Alphyn Biologics, Inc., a clinical-stage dermatology company, has secured $25,000,000 in new funding from investors. This capital infusion marks a significant milestone for the company, which is dedicated to developing multi-target therapeutics for severe and prevalent skin diseases.
The company's core focus is its AB-101 platform, designed to create first-in-class treatments. Its lead product candidate, AB-101a, is a topical treatment for atopic dermatitis (AD), the most common form of eczema. AB-101a has successfully completed a Phase 2a clinical trial, demonstrating a strong safety profile. The treatment is engineered to uniquely target both the bacterial and immune system components of AD, making it suitable for both infected and non-infected cases. The AB-101 platform itself comprises multiple bioactive compounds, offering diverse mechanisms of action to support a robust pipeline of dermatologic therapeutics.
The $25,000,000 in funding will be instrumental in advancing Alphyn Biologics’ clinical programs. The company plans to use the investment to progress its lead candidate, AB-101a, through subsequent clinical trials. Additionally, the capital will support the continued development and expansion of other candidates within its AB-101 platform, strengthening its pipeline of potential treatments.
This investment underscores confidence in Alphyn Biologics' approach to dermatology and its proprietary platform. Looking ahead, the company aims to accelerate its product development efforts, bringing innovative and effective therapeutic solutions to patients suffering from severe skin conditions, thereby fulfilling its mission to address significant unmet medical needs.
